Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology PipelineNon-Dilutive Grant Funding Advances APVO451 and Validates Trispecific …